0001213900-21-034298.txt : 20210625
0001213900-21-034298.hdr.sgml : 20210625
20210625205140
ACCESSION NUMBER: 0001213900-21-034298
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210621
FILED AS OF DATE: 20210625
DATE AS OF CHANGE: 20210625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vivo Capital Fund IX, L.P.
CENTRAL INDEX KEY: 0001750117
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39614
FILM NUMBER: 211049674
BUSINESS ADDRESS:
STREET 1: 192 LYTTON AVENUE
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 688-0818
MAIL ADDRESS:
STREET 1: 192 LYTTON AVENUE
CITY: PALO ALTO
STATE: CA
ZIP: 94301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vivo Capital IX, LLC
CENTRAL INDEX KEY: 0001750698
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39614
FILM NUMBER: 211049675
BUSINESS ADDRESS:
STREET 1: 192 LYTTON AVENUE
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: 6506880818
MAIL ADDRESS:
STREET 1: 192 LYTTON AVENUE
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001819790
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 814717861
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: (949) 409-9820
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
4
1
ownership.xml
X0306
4
2021-06-21
0
0001819790
Tarsus Pharmaceuticals, Inc.
TARS
0001750698
Vivo Capital IX, LLC
C/O VIVO CAPITAL LLC
192 LYTTON AVENUE
PALO ALTO
CA
94301
0
0
1
0
0001750117
Vivo Capital Fund IX, L.P.
C/O VIVO CAPITAL LLC
192 LYTTON AVENUE
PALO ALTO
CA
94301
0
0
1
0
Common Stock
2021-06-21
4
S
0
91620
29.7
D
3153015
I
See Footnote
Common Stock
2021-06-22
4
S
0
110000
28.5
D
3043015
I
See Footnote
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.1 to $29.0, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.0 to $28.1, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.
/s/Frank Kung, Managing Member of Vivo Capital IX, LLC
2021-06-25
/s/Frank Kung, Managing Member of Vivo Capital IX, LLC, General Partner of Vivo Capital Fund IX, L.P.
2021-06-25